Prevalence of right-left shunt in stroke patients with cancer.

Acute ischemic stroke Cancer Echocardiography Patent foramen ovale Right-left shunt Venous thromboembolism

Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
30 May 2024
Historique:
medline: 31 5 2024
pubmed: 31 5 2024
entrez: 31 5 2024
Statut: aheadofprint

Résumé

Cancer is associated with an increased risk of acute ischemic stroke (AIS) and venous thromboembolism. The role of a cardiac right-left shunt (RLS) as a surrogate parameter for paradoxical embolism in cancer-related strokes is uncertain. We sought to investigate the relationship between the presence of a RLS and cancer in AIS patients. We included consecutive AIS patients hospitalized at our tertiary stroke center between January 2015 and December 2020 with available RLS status as detected on transesophageal echocardiography (TEE). Active cancers were retrospectively identified and the association with RLS was assessed with multivariable logistic regression and inverse probability of treatment weighting to minimize the ascertainment bias of having a TEE obtained. Of the 2236 AIS patients included, 103 (4.6%) had active cancer, of whom 24 (23%) were diagnosed with RLS. A RLS was present in 774 out of the 2133 AIS patients without active cancer (36%). After adjustment and weighting, the absence of RLS was associated with active cancer (adjusted odds ratio [aOR], 2.29; 95% confidence interval [CI], 1.14-4.58). When analysis was restricted to patients younger than 60 years or those with a high-risk RLS (Risk of Paradoxical Embolism Score ≥6), there was no association between RLS and cancer (aOR, 3.07; 95% CI, 0.79-11.88 and aOR, 0.56; 95% CI 0.10-3.10, respectively). RLS was diagnosed less frequently in AIS patients with cancer than in cancer-free patients, suggesting that arterial sources may play a larger role in cancer-related strokes than paradoxical venous embolization. Future studies are needed to validate these findings and evaluate potential therapeutic implications such as the general indication, or lack thereof, for PFO closure in this patient population.

Sections du résumé

BACKGROUND AND OBJECTIVES UNASSIGNED
Cancer is associated with an increased risk of acute ischemic stroke (AIS) and venous thromboembolism. The role of a cardiac right-left shunt (RLS) as a surrogate parameter for paradoxical embolism in cancer-related strokes is uncertain. We sought to investigate the relationship between the presence of a RLS and cancer in AIS patients.
METHODS UNASSIGNED
We included consecutive AIS patients hospitalized at our tertiary stroke center between January 2015 and December 2020 with available RLS status as detected on transesophageal echocardiography (TEE). Active cancers were retrospectively identified and the association with RLS was assessed with multivariable logistic regression and inverse probability of treatment weighting to minimize the ascertainment bias of having a TEE obtained.
RESULTS UNASSIGNED
Of the 2236 AIS patients included, 103 (4.6%) had active cancer, of whom 24 (23%) were diagnosed with RLS. A RLS was present in 774 out of the 2133 AIS patients without active cancer (36%). After adjustment and weighting, the absence of RLS was associated with active cancer (adjusted odds ratio [aOR], 2.29; 95% confidence interval [CI], 1.14-4.58). When analysis was restricted to patients younger than 60 years or those with a high-risk RLS (Risk of Paradoxical Embolism Score ≥6), there was no association between RLS and cancer (aOR, 3.07; 95% CI, 0.79-11.88 and aOR, 0.56; 95% CI 0.10-3.10, respectively).
CONCLUSIONS UNASSIGNED
RLS was diagnosed less frequently in AIS patients with cancer than in cancer-free patients, suggesting that arterial sources may play a larger role in cancer-related strokes than paradoxical venous embolization. Future studies are needed to validate these findings and evaluate potential therapeutic implications such as the general indication, or lack thereof, for PFO closure in this patient population.

Identifiants

pubmed: 38816936
doi: 10.1177/17474930241260589
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17474930241260589

Auteurs

Fabienne Steinauer (F)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.
equal contribution.

Philipp Buecke (P)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.
equal contribution.

Eric Buffle (E)

Department of Cardiology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.
ARTORG Center, University of Bern, Bern, Switzerland.

Mattia Branca (M)

CTU Bern, Department of Clinical Research, University of Bern, Bern, Switzerland.

Jayan Göcmen (J)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.

Babak Benjamin Navi (BB)

Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, New York, USA.

Ava Liberman (A)

Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, New York, USA.

Anna Boronylo (A)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.

Leander Clénin (L)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.

Martina Beatrice Goeldlin (MB)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.

Julian Lippert (J)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.

Bastian Volbers (B)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.

Thomas Meinel (T)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.

David J Seiffge (DJ)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.

Adnan Mujanovic (A)

Institute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.

Johannes Kaesmacher (J)

Institute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland.

Urs Fischer (U)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.
Neurology Department, University Hospital of Basel, University of Basel, Basel, Switzerland.

Marcel Arnold (M)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.

Thomas Pabst (T)

Department of Medical Oncology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.

Martin Berger (M)

Department of Medical Oncology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.

Simon Jung (S)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.
equal contribution.

Morin Beyeler (M)

Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland.
Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, New York, USA.
Graduate School for Health Sciences, University of Bern, Switzerland.
equal contribution.

Classifications MeSH